IDEAS home Printed from https://ideas.repec.org/p/sek/iacpro/4006562.html
   My bibliography  Save this paper

Mergers And Acquisit?ons In Pharmaceutical Industry As A Growth Strategy: An Investigation Upon Practice

Author

Listed:
  • Yasin Ç?LHOROZ

    (Hacettepe University)

  • Cuma SON?UR

    (Hacettepe University)

  • Mehmet GÖZLÜ

    (Hacettepe University)

  • Murat KONCA

    (Hacettepe University)

Abstract

Until the begining of 1990s, firms had been looking ways to attain the competitive advantage and increase their profitabilites depending on it by realizing economies of scale or benefiting from market failure. Nowadays, with the impact of globalization, particularly great companies have started to purchase other firms or merge with them as a growth strategy. Pharmaceutical industry has the first place where the mergers and acquisitions occur mostly. Among the drives that leads pharmaceutical firms to mergers or acquisitions; high costs of research and development, economies of scale, motivation for new markets, efforts to improve the existing marketing possibilities, trying to keep up with competition can be counted. The aim of this study is to discuss mergers and acqusisitions in pharmaceutical sector and to evaluate global pharmaceutical industry in this terms.

Suggested Citation

  • Yasin Ç?LHOROZ & Cuma SON?UR & Mehmet GÖZLÜ & Murat KONCA, 2016. "Mergers And Acquisit?ons In Pharmaceutical Industry As A Growth Strategy: An Investigation Upon Practice," Proceedings of International Academic Conferences 4006562, International Institute of Social and Economic Sciences.
    • Handle: RePEc:sek:iacpro:4006562
    as

    Download full text from publisher

    File URL: https://iises.net/proceedings/24th-international-academic-conference-barcelona/table-of-content/detail?cid=40&iid=024&rid=6562
    File Function: First version, 2016
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Joseph A. Clougherty & Tomaso Duso, 2009. "The Impact of Horizontal Mergers on Rivals: Gains to Being Left Outside a Merger," Journal of Management Studies, Wiley Blackwell, vol. 46(8), pages 1365-1395, December.
    2. Patricia M. Danzon & Andrew Epstein & Sean Nicholson, 2007. "Mergers and acquisitions in the pharmaceutical and biotech industries," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 28(4-5), pages 307-328.
    3. Ottorino Morresi & Alberto Pezzi, 2014. "Cross-border Mergers and Acquisitions," Palgrave Macmillan Books, Palgrave Macmillan, number 978-1-137-35762-5, December.
    4. Simon Pilsbury & Andrew Meaney, 2009. "Are Horizontal Mergers and Vertical Integration a Problem?," OECD/ITF Joint Transport Research Centre Discussion Papers 2009/4, OECD Publishing.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. О. A. Yeremchenko, 2018. "Alternative strategies for investing in corporate R&D (on the example of the global pharmaceutical industry)," Economics of Science, Delo Publishing house, vol. 4(4).

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Yasin Ç?LHOROZ & Cuma SON?UR & Mehmet GÖZLÜ & Murat KONCA, 2016. "Mergers And Acquisit?ons In Pharmaceutical Industry As A Growth Strategy: An Investigation Upon Practice," International Journal of Business and Management, International Institute of Social and Economic Sciences, vol. 4(3), pages 1-12, August.
    2. Haucap, Justus & Rasch, Alexander & Stiebale, Joel, 2019. "How mergers affect innovation: Theory and evidence," International Journal of Industrial Organization, Elsevier, vol. 63(C), pages 283-325.
    3. Christos Genakos & Andreas Lamprinidis & James Walker, 2023. "Evaluating merger effects," CEP Discussion Papers dp1921, Centre for Economic Performance, LSE.
    4. Valérie Revest & Alessandro Sapio, 2016. "Graduation and sell-out strategies in the Alternative Investment Market," Discussion Papers 4_2016, CRISEI, University of Naples "Parthenope", Italy.
    5. Gugler, Klaus & Szücs, Florian, 2013. "Spillover effects in oligopolistic markets," VfS Annual Conference 2013 (Duesseldorf): Competition Policy and Regulation in a Global Economic Order 79905, Verein für Socialpolitik / German Economic Association.
    6. Luca Verginer & Federica Parisi & Jeroen van Lidth de Jeude & Massimo Riccaboni, 2022. "The Impact of Acquisitions in the Biotechnology Sector on R&D Productivity," Papers 2203.12968, arXiv.org, revised Jan 2024.
    7. Bamiatzi, Vassiliki & Efthyvoulou, Georgios & Jabbour, Liza, 2017. "Foreign vs domestic ownership on debt reduction: An investigation of acquisition targets in Italy and Spain," International Business Review, Elsevier, vol. 26(5), pages 801-815.
    8. Elisa Barbieri & Manli Huang & Shenglei Pi & Mattia Tassinari, 2017. "Restructuring the Production of Medicines: An Investigation on the Pharmaceutical Sector in China and the Role of Mergers and Acquisitions," IJERPH, MDPI, vol. 14(10), pages 1-21, October.
    9. Maé Geymond, 2020. "The influence of local institutional and historical frameworks on a globalized industry: The case of the pharmaceutical industry in France and Quebec," Post-Print halshs-02900915, HAL.
    10. Jinhee Kwon & Cheong Kim & Kun Chang Lee, 2020. "Moderating Effect of the Continental Factor on the Business Strategy and M&A Performance in the Pharmaceutical Industry for Sustainable International Business," Sustainability, MDPI, vol. 12(12), pages 1-14, June.
    11. Anna Rita Bennato & Stephen Davies & Franco Mariuzzo & Peter Ormosi, 2019. "Mergers and Innovation: Evidence from the Hard Disk Drive Market," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2018-04v3, Centre for Competition Policy, University of East Anglia, Norwich, UK..
    12. Akdoğu, Evrim & Simsir, Serif Aziz, 2023. "Are blockchain and cryptocurrency M&As harder to close?," Finance Research Letters, Elsevier, vol. 52(C).
    13. Jan Malek & Melissa Newham & Jo Seldeslachts & Reinhilde Veugelers, 2024. "Acquiring R&D projects: who, when, and what? Evidence from antidiabetic drug development," Working Papers of Department of Management, Strategy and Innovation, Leuven 735739, KU Leuven, Faculty of Economics and Business (FEB), Department of Management, Strategy and Innovation, Leuven.
    14. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    15. Tannista Banerjee & Arnab Nayak, 2015. "Comparing Domestic and Cross-Border Mergers and Acquisitions in the Pharmaceutical Industry," Atlantic Economic Journal, Springer;International Atlantic Economic Society, vol. 43(4), pages 489-499, December.
    16. Bennato, Anna Rita & Davies, Stephen & Mariuzzo, Franco & Ormosi, Peter, 2021. "Mergers and innovation: Evidence from the hard disk drive market," International Journal of Industrial Organization, Elsevier, vol. 77(C).
    17. Mahdiyeh Entezarkheir & Saeed Moshiri, 2021. "Innovation spillover and merger decisions," Empirical Economics, Springer, vol. 61(5), pages 2419-2448, November.
    18. Walter Park & Ralph Sonenshine, 2012. "Impact of Horizontal Mergers on Research & Development and Patenting: Evidence from Merger Challenges in the U.S," Journal of Industry, Competition and Trade, Springer, vol. 12(1), pages 143-167, March.
    19. Lars Calmfors & Giancarlo Corsetti & Seppo Honkapohja & Gilles Saint-Paul & Hans-Werner Sinn & John Kay & Jan-Egbert Sturm & Xavier Vives, 2006. "Chapter 5: Mergers and Competition Policy in Europe," EEAG Report on the European Economy, CESifo, vol. 0, pages 101-116, March.
    20. Duso, Tomaso & Gugler, Klaus & Yurtoglu, Burcin B., 2011. "How effective is European merger control?," European Economic Review, Elsevier, vol. 55(7), pages 980-1006.

    More about this item

    Keywords

    Merger; Acquisition; Growth Strategy; Pharmaceutical Industry;
    All these keywords.

    JEL classification:

    • F23 - International Economics - - International Factor Movements and International Business - - - Multinational Firms; International Business
    • G34 - Financial Economics - - Corporate Finance and Governance - - - Mergers; Acquisitions; Restructuring; Corporate Governance
    • L65 - Industrial Organization - - Industry Studies: Manufacturing - - - Chemicals; Rubber; Drugs; Biotechnology; Plastics

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sek:iacpro:4006562. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Klara Cermakova (email available below). General contact details of provider: https://iises.net/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.